Bacterial Gastritis: Causes, Clinical Implications, and Management

Introduction to Bacterial Gastritis

Helicobacter pylori is the most significant bacterial cause of gastritis, responsible for 71-95% of all gastric cancer cases, according to the American Gastroenterological Association 1

H. pylori Gastritis

H. pylori is the primary bacterial cause of gastritis, recognized as the most important factor in the pathogenesis of chronic gastritis, as stated by the European Helicobacter Study Group 2, 1
The pattern of gastritis affects acid secretion - antral-predominant gastritis leads to increased acid production, while body-predominant gastritis causes decreased acid production, as noted by the American College of Gastroenterology 1
Corpus-predominant H. pylori gastritis substantially increases the risk for gastric cancer development, according to the National Comprehensive Cancer Network 1

Progression and Complications of Bacterial Gastritis

H. pylori gastritis can progress through a cascade: chronic active gastritis → atrophic gastritis → intestinal metaplasia → gastric cancer, as described by the World Gastroenterology Organisation 3
The lifetime risk of peptic ulcer disease is approximately 17% in those infected with H. pylori, as reported by the American Gastroenterological Association 4
Gastric cancer is the third most common cause of cancer death worldwide, with H. pylori infection increasing the risk by approximately 2.5-fold, according to the International Agency for Research on Cancer 1, 5
The risk of progression from atrophic gastritis to gastric adenocarcinoma ranges from 0.1% to 0.3% per year, as stated by the American College of Gastroenterology 1
Eradication of H. pylori infection halts the progression of gastritis, alters the natural history of the disease, and reduces the overall risk of gastric cancer, as noted by the European Helicobacter Study Group 3

Diagnosis of Bacterial Gastritis

H. pylori infection can be diagnosed through non-invasive tests such as urea breath test (UBT) and monoclonal stool antigen tests, as recommended by the American Gastroenterological Association 1
Endoscopy with biopsy allows for histological examination, which can identify both H. pylori and the pattern/severity of gastritis, according to the World Gastroenterology Organisation 3
False positive UBT results can occur in patients with achlorhydria due to overgrowth of non-H. pylori urease-producing organisms, as reported by the American College of Gastroenterology 3

Treatment Implications

Eradication of H. pylori infection is recommended whenever it is diagnosed, as it is now recognized as an infectious disease with significant risk to the host, according to the National Institutes of Health 6
Eradication of H. pylori infection before the development of preneoplastic conditions is most effective in reducing gastric cancer risk, as stated by the European Helicobacter Study Group 2

Clinical Considerations

Specific high-risk populations (Native Americans, blacks, Hispanics, and immigrants from high-risk countries) warrant increased awareness and focused testing for H. pylori, as recommended by the Centers for Disease Control and Prevention 3
In countries with high gastric cancer risk, population-wide H. pylori eradication programs have shown effectiveness in reducing peptic ulcer, premalignant lesions, and gastric cancer incidence, according to the World Health Organization 3

Helicobacter pylori Infection and Gastritis Pathogenesis

Pathophysiology of H. pylori-Associated Gastritis

Atrophic corpus gastritis caused by H. pylori leads to hypochlorhydria, allowing overgrowth of non-H. pylori organisms capable of producing carcinogenic metabolites, and reduces luminal concentrations of ascorbic acid, an antioxidant that scavenges carcinogenic N-nitrosamines and reactive oxygen species 7

Clinical Implications

Gastric cancer is rare in the absence of chronic active gastritis, and the extent and severity of gastritis, along with atrophy and intestinal metaplasia, are positively associated with cancer risk 8
Hereditary diffuse gastric cancer (less than 1% of gastric carcinomas) is not related to H. pylori infection or gastritis 8

Treatment and Prevention

Eradication of H. pylori before the development of preneoplastic conditions is most effective in reducing gastric cancer risk, and H. pylori treatment may improve atrophic gastritis, but intestinal metaplasia is generally considered irreversible 8

H. pylori Eradication and Gastric Cancer Prevention

Cancer Risk and Pathophysiology

H. pylori is causally linked to 71-95% of all gastric cancers, making it the most common proven risk factor for human non-cardiac gastric adenocarcinoma, with epidemiological data showing gastric cancer is rare without chronic active gastritis 9, 10
The infection drives a carcinogenic cascade: chronic active gastritis → atrophic gastritis → intestinal metaplasia → gastric adenocarcinoma, with reduced luminal ascorbic acid in the hypochlorhydric stomach 9, 10
Bacterial virulence factors (CagA and VacA) increase cancer risk, though no specific markers are recommended for clinical testing 11, 12

Treatment to Reduce Cancer Risk

H. pylori eradication to prevent gastric cancer should be undertaken in high-risk populations, including first-degree relatives of patients with gastric cancer, patients with previous gastric neoplasia, and patients with high-risk gastritis patterns 13, 14
The American Gastroenterological Association recommends H. pylori eradication for patients with high-risk gastritis patterns, such as severe pan-gastritis, corpus-predominant gastritis, and severe atrophy 13, 14

Evidence for Cancer Prevention

Strong evidence demonstrates that H. pylori eradication reduces gastric cancer development, with intervention studies in Japan, Colombia, and China confirming eradication effectiveness 11, 9, 10
The strategy is most cost-effective in populations with high gastric cancer rates, according to the National Comprehensive Cancer Network 14
The European Society of Gastrointestinal Endoscopy recommends H. pylori eradication as a cost-effective strategy for gastric cancer prevention in high-risk populations 14

Timeframe for H. pylori to Cause Gastric Cancer

Critical Factors Affecting Timeline

Intestinal metaplasia (IM) represents a critical point of no return, with gastric cancer developing 10.9 times more frequently in the presence of IM, and IM is generally considered irreversible even after H. pylori eradication, according to the European Society of Gastrointestinal Endoscopy 15
Environmental factors and host genetics modulate the timeline, though H. pylori infection remains the dominant factor, with environmental influences being subordinate, as stated by the European Society of Gastrointestinal Endoscopy 15

Clinical Implications for Prevention

Eradication before the development of preneoplastic conditions (atrophy and IM) is most effective in reducing gastric cancer risk, with level 1a evidence supporting this approach, recommended by the National Institute for Health and Care Excellence 15
Gastric atrophy may be reversible only in the corpus, but not in the antrum, and there is uniform agreement that intestinal metaplasia is irreversible, as stated by the American Gastroenterological Association 15

Important Caveats

Hereditary diffuse gastric cancer (less than 1% of cases) is not related to H. pylori infection and follows a different timeline driven by CDH-1 gene mutations, according to the International Gastric Cancer Linkage Consortium 15

Incidence of Malignant Gastric Ulcers

Population-Level Incidence Data

The American Cancer Society estimates that approximately 1% of individuals with H. pylori infection develop gastric malignancies over their lifetime, with higher rates in older adults and those from high-risk regions 16
In the United Kingdom, there are approximately 10,000 new gastric cancer diagnoses annually, with an incidence of 20.4 per 100,000 for men and 7.4 per 100,000 for women, according to the National Health Service 17
Globally, gastric cancer is the sixth most common cancer worldwide with 1,089,103 new cases diagnosed in 2020 and over 768,793 deaths, as reported by the World Health Organization 16
Over 80% of gastric cancer cases are diagnosed after age 65, making this predominantly a disease of older adults, according to the National Institute on Aging 17

Risk of Malignancy in H. pylori-Infected Individuals

The lifetime risk of gastric malignancy is approximately 1% in H. pylori-infected individuals, though this varies dramatically by geography from 0.6% in the United States to 20% in high-risk countries like Japan and China, as stated by the Centers for Disease Control and Prevention 16
The infection increases gastric cancer risk by approximately 2.5-fold overall, with some studies showing up to 6-fold increased risk, according to the American Gastroenterological Association 17

High-Risk Populations with Elevated Incidence

Early-generation immigrants from moderate-to-high incidence regions, such as Eastern Europe, Andean Latin America, and East Asia, have a higher incidence of gastric cancer, as reported by the International Agency for Research on Cancer 18, 19

H. pylori Colonization in the Gastric Antrum

Anatomical Distribution Pattern

The gastric antrum has a higher pH environment, making it more hospitable for H. pylori bacterial survival, according to the European Society of Gastrointestinal Endoscopy 20
Bacterial density is highest in the antrum in typical H. pylori infections, which is why diagnostic biopsies are routinely taken from this region to maximize detection rates, as recommended by the American Gastroenterological Association 21

Clinical Implications of Antral Colonization

Sampling strategy matters: while a single antral biopsy yields >90% sensitivity, examining at least two samples from both the antrum and body substantially improves diagnostic accuracy, as suggested by the National Institute of Diabetes and Digestive and Kidney Diseases 21
Proton pump inhibitors alter the distribution of H. pylori, causing bacterial load to decrease especially in the antrum, leading to 10-40% false-negative diagnostic test results, according to the British Society of Gastroenterology 20

Important Diagnostic Considerations

Clinicians should stop proton pump inhibitors for 2 weeks before biopsy-based testing to allow bacteria to repopulate the antrum and avoid false-negatives, as recommended by the European Helicobacter Study Group 20
Multiple biopsy sites are essential: standard practice requires at least two biopsies from the antrum and two from the body, plus one for rapid urease testing, to account for patchy distribution, as suggested by the World Gastroenterology Organisation 22, 23

CagA Virulence Factor and Its Clinical Implications

Prevalence of CagA‑Positive Helicobacter pylori Strains

Approximately 70 % of H. pylori strains isolated from European populations carry the cag pathogenicity island encoding the CagA oncoprotein. 24

Association of CagA with Disease Outcomes

Infection with CagA‑positive H. pylori strains is linked to a higher risk of developing peptic ulcer disease, atrophic gastritis, and gastric cancer compared with infection by CagA‑negative strains. 24

Evidence‑Based Guidelines for Diagnosis and Management of Helicobacter pylori Infection

Pathophysiology

All individuals infected with H. pylori develop chronic gastritis, irrespective of symptom presence, indicating that the infection invariably induces mucosal inflammation. 25

Symptom Assessment

Upper abdominal pain or dyspepsia occurs with comparable frequency in H. pylori‑positive and ‑negative patients, demonstrating that this symptom is not discriminative for infection status. 26
Symptom‑based diagnosis is unreliable; patients with confirmed infection report symptom patterns indistinguishable from those without infection, necessitating objective testing for accurate diagnosis. 26

Diagnostic Recommendations

The “test‑and‑treat” strategy is advised for uninvestigated dyspepsia in populations where H. pylori prevalence exceeds 20 %. Recommended non‑invasive tests include the urea breath test or monoclonal stool antigen assay. This recommendation aligns with gastroenterology society guidelines (e.g., American College of Gastroenterology). 26
Testing should be guided by risk factors, alarm features, or the presence of any dyspeptic symptoms in high‑prevalence settings, rather than awaiting a specific symptom constellation. 25

Treatment Outcomes

Eradication therapy yields long‑term symptom relief in only about 1 in 12 patients with functional dyspepsia, yet it is critical for preventing progression to gastric cancer. 26